Azerbaijan vs IDA total: Access to anti-retroviral drugs, female
Azerbaijan
98.0%
in 2024
IDA total
87.1%
in 2024
Azerbaijan rank
1st
IDA total rank
4th
Access to anti-retroviral drugs, female over time
- Azerbaijan
- IDA total
How they compare
Azerbaijan currently reports 98.0% against 87.1% in IDA total, a difference of 10.9%.
That makes Azerbaijan's figure about 1.1 times IDA total's.
The two have swapped places 3 times across 24 shared years of data; in 2000 it was IDA total ahead.
Azerbaijan ranks 1st and IDA total ranks 4th of 141 countries.
Across the 3 decades both report, Azerbaijan averaged higher in 1 and IDA total in 2.
Head to head by decade
| Decade | Azerbaijan | IDA total | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.0% | 5.7% | 4.7% | IDA total |
| 2010s | 32.0% | 48.9% | 16.9% | IDA total |
| 2020s | 83.6% | 80.9% | 2.7% | Azerbaijan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Azerbaijan or IDA total?
- Azerbaijan, at 98.0% against 87.1% in IDA total as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Azerbaijan and IDA total?
- 10.9%, with Azerbaijan ahead.
- How many years of comparable data are there for Azerbaijan and IDA total?
- 24 years are reported by both, from 2000 to 2024.
- How do Azerbaijan and IDA total rank globally for access to anti-retroviral drugs, female?
- Azerbaijan ranks 1st and IDA total ranks 4th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.